Study of TROP2 CAR/IL-15 TGFBR2 KO NK Cells for Gastric Cancer
This study is testing a new treatment for stomach cancer (gastric cancer) that has spread to the lining of the abdomen (peritoneum). Researchers want to find the right dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells, which are special immune cells, given directly into the stomach area. You would also receive Rimiducid, Fludarabine, and Cyclophosphamide by IV. The main goal is to check the safety of this treatment and see if it causes any side effects. Researchers will also look at how well the treatment works. This study is for adults aged 18 and older. The study is currently recruiting an estimated 10 participants, but the overall status is unclear.
- Study design
- This is a Phase 1/2 study, meaning it's an early-stage trial to determine safety and dosage. It plans to enroll 10 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for safety and side effects throughout the study completion, which is an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Brian D Badgwell, MD · PRINCIPAL_INVESTIGATOR · UT MD Anderson
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0